Here, Victoria Meyer, Senior Global Strategic Marketing Manager at BD Medical – Pharmaceutical Systems, introduces the BD SCF™ PremiumCoat® 1mlL Plunger Stopper and explains how the product’s role is critical in determining combination products’ exposure to extractables and leachables.

As high dose biologic formulations push the limits of self injection into 1 2 ml formats and beyond, delivery systems that are intuitive and easy to use, and targeted to specific user populations, are becoming increasingly necessary.

Aurélie Pager, Clinical and Human Factors Program Leader; Brigitte Duinat, Senior Engineer; and Barbara Alves, Regulatory Affairs Specialist, all of BD Medical – Pharmaceutical Systems, reporting on several patient studies, look at how new BD Neopak™ XtraFlow™ prefillable glass-based syringes with shorter, 8 mm needles and thinner wall cannula technology are set to improve the injection experience for subcutaneous drug delivery in chronic care.

BD is teaming up with partners in tagging and traceability technologies to develop a comprehensive solution to deliver traceability at the unique container level.

Article describing capabilities of BD Evolve™ On-Body Injector system to elicit customer needs

Learn about how shorter 8mm and thinner wall canual needle technology can improve subcutaneous chronic drug delivery and patient injection experience.

Learn about how shorter 8mm and thinner wall canual needles can improve subcutaneous chronic drug delivery from an end-user (patient) perspective.

Learn more about the potential risks in combination product development, the limits of existing self-injection systems and the challenge of reconciling competing design requirements.

This article highlights the need for a commercially proven AI to support biosimilar development in an increasingly competitive environment. The article walks through the features, benefits and value a BD Physioject can provide during combination product development.

BD Vystra™ Disposable Pen - Introductory Overview One Pager